

Press Release

Contact:

Philip G. Ralston, Jr.
214.577.5999
Pralston@macuclear.com

2300 McDermott Road
Suite 200-147
Plano, Texas 75025
www.macuclear.com

MacuCLEAR secures Pre IND meeting with FDA March meeting with FDA will define future clinical program

Plano, TX; February 27, 2008: MacuCLEAR, Inc. announced it has secured a Pre IND meeting with the FDA's Division of Anti-Infective and Ophthalmology in the Center for Drug Evaluation and Research. The purpose of this meeting is for MacuCLEAR to review its preclinical data with a panel of Division experts and get concurrence with its proposed human clinical program. "MacuCLEAR looks forward to this meeting with FDA and the opportunity to discuss our preclinical animal data, safety, toxicology and formulation stability studies and our proposed Phase I/II human clinical trials," said Philip G. Ralston, Jr., President and CEO. "We are confident we will receive a positive review of our preclinical program and a reasonable program for future human clinical trials. Our lead compound, MC1101, is based on a previously approved compound by the FDA that has been in use for over 50 years. Its safety and toxicology profile is well characterized. Further, there is a compelling need for a solution for the growing problem of age related macular degeneration. Currently, there is no approved treatment for the early stage or dry form of this debilitating disease," said Ralston. MacuCLEAR will begin filing its IND based on the outcome of this meeting. Once submitted, the FDA has 30 days to review the IND application. MacuCLEAR could begin human clinical trials after 30 days if it receives a go from the FDA.

About MacuCLEAR: Texas based, MacuCLEAR, Inc. is a specialty pharmaceutical development company. Its lead compound, MC1101 is a novel, topically delivered solution for the treatment and prevention of the progression of the Dry or early stage of age related macular degeneration, which afflicts 90% of all who have AMD. This technology was invented at Texas A&M University by George C.Y. Chiou, PhD, who led the development of Timolol, a pioneering treatment for glaucoma.